Skip to main content
Clinical Trials/NCT03958526
NCT03958526
Unknown
Not Applicable

Effectiveness of Transcranial Direct Current Stimulation in Chronic Pain Related to Lumbar Spinal Stenosis

Istanbul University1 site in 1 country32 target enrollmentApril 1, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Lumbar Spinal Stenosis
Sponsor
Istanbul University
Enrollment
32
Locations
1
Primary Endpoint
Changes in Pain as measured by Visual Analog Scale
Last Updated
6 years ago

Overview

Brief Summary

Transcranial Direct Current Stimulation (tDCS) is a promising non-invasive brain stimulation technique in chronic pain. There is no study investigating the effectiveness of tDCS in radiating chronic lower extremity pain related to lumbar spinal stenosis (LSS). The aim of this study is to investigate the effects of tDCS on pain, walking capacity, functional status and quality of life in patients with chronic pain related to LSS.

32 patients diagnosed with chronic pain related to LSS will be enrolled in this prospective, randomized, double blind, placebo-controlled study according to inclusion/exclusion criteria. Patients in active group will receive 10 sessions of anodal tDCS delivered over primary motor cortex (M1) with a constant current of 2 miliAmpers for 20 minutes. Patients will be evaluated at baseline, on day 1, 5 and 10 (after the session) and 5 days, 1 month and 3 months after treatment.

Registry
clinicaltrials.gov
Start Date
April 1, 2019
End Date
October 31, 2019
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Enes Efe Is

Principal Investigator

Istanbul University

Eligibility Criteria

Inclusion Criteria

  • Magnetic resonance imaging evidence of narrowing of the central canal, lateral recess, and/or foramen.
  • Persistent leg pain for at least 3 months
  • An average pain intensity score (during walking) of at least 4 out of 10 on the Visual Analog Scale at screening and randomisation
  • Persistent neurogenic claudication for at least 3 months
  • stable pharmacological treatment for pain and sleep disorders for at least 1 month before the study and throughout the trial
  • If present, coexisting low back pain intensity should be less than leg pain intensity.

Exclusion Criteria

  • Patients with other neurological or psychiatric disorders including ongoing major depression (Beck Depression Score\>14)
  • Uncontrolled/unstable endocrinologic, cardiovascular, pulmonary, hematologic, hepatic, renal disease
  • Inflammatory diseases, cancer
  • Severe hip and/or knee osteoarthritis that affects Treadmill Walking Test
  • Absolute/relative contraindications of tDCS (past head trauma resulting with loss of consciousness, epilepsy, past neurosurgical intervention, intracranial hypertension, implanted devices, migraine, chronic-severe headache episodes, a history of side effects with non-invasive brain stimulation techniques, skin diseases, pregnancy)

Outcomes

Primary Outcomes

Changes in Pain as measured by Visual Analog Scale

Time Frame: 12 weeks

The visual analog scale for pain is a straight line, 10 centimeters (10 cm) in length with one end meaning no pain and the other end meaning the worst pain imaginable. A patient marks a point on the line that matches the amount of pain he or she feels. A higher score indicates greater pain intensity (0 (min)-10 (max)) .

Walking Duration and Distance

Time Frame: 12 weeks

Patients will be asked to walk on a treadmill at zero angle and a self-selected speed until they have to stop due to symptoms of LSS or until a time limit of 30 minutes has been reached. To start the test, the investigator slowly increases the speed to 1.9 km per hour. The subjects will be then allowed to modify the speed during the test to maintain a pace that is comfortable for them. Subjects will be asked to notify the investigator when they first experience a change in symptoms. Subjects will be also asked to avoid holding the handle bars. Total distance and time, distance and time to onset of symptoms will be measured.

Secondary Outcomes

  • Changes in Functional Status(12 weeks)
  • Changes in Quality of Life: Short Form-36(12 weeks)

Study Sites (1)

Loading locations...

Similar Trials